Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...

Novavax performed well last year, but the company's shares are down significantly over the past three years and are not far ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Research offering unprecedented insights into global vaccine distribution patterns has found significant disparities in COVID ...

Cornell researchers have developed a stable, multi-target vaccine offering long-lasting protection against COVID-19 and influenza, with promising results in mice. Cornell University researchers have ...